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A B S T R A C T
The broth microdilution method for telavancin susceptibility testing was revised and now utilises DMSO
as solvent for stock solution preparation and diluent for stock solution dilution, following CLSI guidelines
for water-insoluble agents. The revised method also incorporates polysorbate 80 in the test medium to
mitigate drug binding to plastics. This revised methodology provides more accurate and reproducible
MIC determinations, which results in values lower than the previously established method. This study
was conducted to re-establish telavancin potencies and susceptibility proﬁles (using updated
interpretive criteria) against a collection of uncommon clinical pathogens (3821 isolates). Telavancin
showed MIC50 values of 0.06 mg/L against tested staphylococcal species (MIC50/90, 0.03/0.06 mg/L; 98.1–
100.0% susceptible), with lower results for Staphylococcus hominis (MIC50, 0.015 mg/L), Staphylococcus
lugdunensis (MIC50, 0.015 mg/L) and Staphylococcus simulans (MIC50, 0.03 mg/L). Vancomycin (MIC50,
1 mg/L), daptomycin (MIC50, 0.12–1 mg/L) and linezolid (MIC50, 0.25–1 mg/L) had MIC50 results at least
four-fold higher than telavancin against CoNS. Streptococci (99.2–100.0% susceptible) displayed
telavancin MIC50 values of 0.015–0.03 mg/L. Vancomycin (MIC50, 0.25–0.5 mg/L) and linezolid (MIC50,
0.5–1 mg/L) had higher MIC50 results against streptococci, whilst daptomycin MIC50 values varied from
0.06 mg/L to 0.5 mg/L. Micrococcus, Listeria and Corynebacterium spp. were inhibited by telavancin at
0.015, 0.03 and 0.06 mg/L, respectively. Telavancin exhibited potent in vitro activity against this
collection, greater than comparators (daptomycin, linezolid, vancomycin). This study provides new
baseline MIC results for telavancin and conﬁrms the spectrum and potency of telavancin against less
commonly encountered Gram-positive species.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Chemotherapy of
Infection and Cancer. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Telavancin was approved in 2009 in North America (USA and
Canada) for the treatment of adults with complicated skin and
soft-tissue infections (cSSTI) caused by susceptible organisms. In
addition, it was granted approval in the USA and Europe for the
treatment of adult patients with hospital-acquired and ventilator-
associated bacterial pneumonia caused by susceptible isolates of
Staphylococcus aureus [meticillin-resistant S. aureus (MRSA) only* Corresponding author at: JMI Laboratories, 345 Beaver Kreek Centre, Suite A,
North Liberty, IA 52317, United States. Tel.: +1 319 665 3370x218;
fax: +1 319 665 3371.
E-mail address: rodrigo-mendes@jmilabs.com (R.E. Mendes).
http://dx.doi.org/10.1016/j.jgar.2014.12.003
2213-7165/ 2015 The Authors. Published by Elsevier Ltd on behalf of International Socie
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).in Europe] when alternative treatments are not suitable [1].
Telavancin possesses concentration-dependent bactericidal ac-
tivity due to a dual mechanism of action combining inhibition of
cell wall synthesis and disruption of bacterial cell membrane
function [2]. These mechanisms of action provide potent
antimicrobial activity for telavancin against a broad range of
Gram-positive organisms, which has been reported in several
previous studies [3–6].
Broth microdilution susceptibility testing method for telavan-
cin was revised to accommodate modiﬁcations associated with
preparation of telavancin stock solution and dilution, which now
follow the current Clinical and Laboratory Standards Institute
(CLSI) guidelines for water-insoluble agents [7,8]. Moreover, this
revised method also includes the addition of 0.002% polysorbate 80
to the test medium, which has been shown to reduce the binding ofty for Chemotherapy of Infection and Cancer. This is an open access article under the
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method was approved by the CLSI [9] and the US Food and Drug
Administration (FDA) [1]. This revised method provides more
accurate, precise and reproducible telavancin minimum inhibitory
concentration (MIC) determinations; however, these results are
lower than those obtained by the previously established method
[7,8]. Therefore, this study was performed to establish the activity
and spectrum of telavancin when using a revised microdilution
method tested against a worldwide collection of rarely isolated
clinical pathogens.
2. Materials and methods
2.1. Bacterial strains
A total of 3821 consecutive, non-duplicate, Gram-positive
clinical isolates were included in this study, which were collected
from medical centers located in 12 countries in the Asia-Western
Paciﬁc region (35 sites), 21 countries in Europe and Israel (53
sites), 11 countries in Latin America (21 sites) and 2 countries in
North America (110 sites). These isolates were recovered
primarily from bacteraemia (44%), SSTI (28%) and respiratory
tract infections (8%), deemed clinically relevant by local guide-
lines and submitted to a central monitoring laboratory (JMI
Laboratories, North Liberty, IA) as part of the SENTRY Antimicro-
bial Surveillance Program for 2011–2013. Isolates were initially
identiﬁed by the participating laboratory and the identiﬁcation
was conﬁrmed by the reference monitoring laboratory (JMITable 1
Telavancin activity and minimum inhibitory concentration (MIC) distribution against a
Genus MIC (mg/L) No. (cu
Group
Species (no. tested) MIC50 MIC90 0.015
Staphylococcus spp. (1656)
Staphylococcus intermedius (11) 0.015 0.015 10 (90
Staphylococcus lugdunensis (258) 0.015 0.03 147 (57
Staphylococcus hominis (414) 0.015 0.06 228 (55
Staphylococcus simulans (48) 0.03 0.06 0 (0.
Staphylococcus haemolyticus (425) 0.06 0.06 24 (5.
Staphylococcus caprae (42) 0.06 0.06 1 (2.
Staphylococcus cohnii (27) 0.06 0.06 1 (3.
Staphylococcus capitis (214) 0.06 0.06 24 (11
Staphylococcus warneri (93) 0.06 0.06 4 (4.
Staphylococcus saprophyticus (106) 0.06 0.12 3 (2.
Staphylococcus pettenkoferi (18) 0.06 0.12 0 (0.
Viridans group streptococci (1939)
Streptococcus anginosus group (627) 0.015 0.03 371 (59
Streptococcus anginosus (434) 0.015 0.03 227 (52
Streptococcus constellatus (157) 0.015 0.03 119 (75
Streptococcus intermedius (36) 0.015 0.06 25 (69
Streptococcus mitis group (1039) 0.015 0.03 604 (58
Streptococcus mitis/oralis (788) 0.015 0.03 488 (61
Streptococcus sanguinis (113) 0.015 0.03 58 (51
Streptococcus gordonii (37) 0.03 0.06 15 (40
Streptococcus parasanguinis (101) 0.03 0.03 43 (42
Other viridans group streptococci
Streptococcus salivarius (123) 0.015 0.03 77 (62
Streptococcus vestibularis (10) 0.015 0.015 9 (90
Streptococcus bovis/gallolyticus (126) 0.03 0.03 61 (48
Streptococcus mutans (14) 0.03 0.06 3 (21
b-streptococci (157)
Streptococcus dysgalactiae (143) 0.015 0.03 109 (76
Streptococcus equisimilis (14) 0.015 0.06 7 (50
Other genera (69)
Micrococcus spp. (11) 0.015 0.015 11 (10
Listeria spp. (24) 0.015 0.03 21 (87
Corynebacterium spp. (34) 0.015 0.03 29 (85
a Modal MIC results are in bold.Laboratories) using standard algorithms and supported by
VITEK1 2 (bioMe´rieux, Hazelwood, MO) and matrix-assisted
laser desorption/ionisation time-of-ﬂight mass spectrometry
(MALDI-TOF/MS) (Bruker Daltonics, Bremen, Germany).
2.2. Antimicrobial susceptibility proﬁle
Isolates were tested for susceptibility by broth microdilution
following the guidelines in CLSI document M07-A9 [10]. Testing
was performed using dry-form panels manufactured by Thermo
Fisher Scientiﬁc (Cleveland, OH). These panels were previously
validated and shown to provide MIC results equivalent to the
revised, and CLSI- and FDA-approved, broth microdilution method
(supplemented with 0.002% polysorbate 80) described above [7].
Bacterial inoculum density was monitored by colony counts to
assure an adequate number of cells for each testing event.
Validation of the MIC values was performed by concurrent testing
of CLSI-recommended quality control reference strains (S. aureus
ATCC 29213, Enterococcus faecalis ATCC 29212 and Streptococcus
pneumoniae ATCC 49619) [9]. All quality control results were
within published acceptable ranges. The FDA-approved breakpoint
for S. aureus (0.12 mg/L) was applied to coagulase-negative
staphylococci (CoNS) [1]. The breakpoint for Streptococcus
anginosus group (0.06 mg/L for susceptible) was utilised for
the interpretation of telavancin MIC results obtained against
viridans group streptococci, whilst the interpretive criterion for
Streptococcus pyogenes and Streptococcus agalactiae (0.12 mg/L
for susceptible) was applied for b-haemolytic streptococci [1]. contemporary (2011–2013) and worldwide collection of clinical isolates.
mulative %) inhibited at a telavancin MIC (mg/L) ofa
 0.03 0.06 0.12 0.25
.9) 1 (100.0)
.0) 98 (95.0) 13 (100.0)
.1) 127 (85.7) 58 (99.8) 1 (100.0)
0) 24 (50.0) 21 (93.8) 3 (100.0)
6) 126 (35.3) 262 (96.9) 13 (100.0)
4) 12 (31.0) 28 (97.6) 1 (100.0)
7) 12 (48.1) 13 (96.3) 1 (100.0)
.2) 72 (44.9) 114 (98.1) 3 (99.5) 1 (100.0)
3) 31 (37.6) 51 (92.5) 7 (100.0)
8) 4 (6.6) 58 (61.3) 39 (98.1) 2 (100.0)
0) 8 (44.4) 4 (66.7) 6 (100.0)
.2) 238 (97.1) 18 (100.0)
.3) 195 (97.2) 12 (100.0)
.8) 36 (98.7) 2 (100.0)
.4) 7 (88.9) 4 (100.0)
.1) 388 (95.5) 46 (99.9) 1 (100.0)
.9) 268 (95.9) 31 (99.9) 1 (100.0)
.3) 49 (94.7) 6 (100.0)
.5) 18 (89.2) 4 (100.0)
.6) 53 (95.0) 5 (100.0)
.6) 38 (93.5) 7 (99.2) 1 (100.0)
.0) 1 (100.0)
.4) 59 (95.2) 6 (100.0)
.4) 9 (85.7) 2 (100.0)
.2) 28 (95.8) 5 (99.3) 1 (100.0)
.0) 5 (85.7) 2 (100.0)
0.0)
.5) 3 (100.0)
.3) 4 (97.1) 1 (100.0)
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3. Results and discussion
Overall, lower telavancin MIC50 results were noted against
Staphylococcus hominis (MIC50, 0.015 mg/L), Staphylococcus inter-
medius (MIC50, 0.015 mg/L), Staphylococcus lugdunensis (MIC50,
0.015 mg/L) and Staphylococcus simulans (MIC50, 0.03 mg/L)
compared with a slightly higher MIC50 value obtained against
other staphylococcal species (MIC50, 0.06 mg/L) (Table 1). The
comparator, daptomycin, also showed a similar activity proﬁle
(MIC50 values) against staphylococci other than S. aureus, with
lower MIC50 results (0.12–0.25 mg/L) for S. hominis, S. intermedius,
S. lugdunensis, S. simulans and Staphylococcus haemolyticus and
higher values (0.5–1 mg/L) against other species (Table 2).
Vancomycin showed constant MIC50 results (1 mg/L) against
CoNS, whilst linezolid MIC50 values varied between 0.25 mg/L
and 1 mg/L. Telavancin demonstrated MIC50 results at least four-
fold lower than these comparators when tested against these
staphylococci; only one Staphylococcus capitis and two Staphylo-
coccus saprophyticus (0.2%) had telavancin MIC results (i.e.
0.25 mg/L) above the susceptible breakpoint for S. aureus (i.e.
0.12 mg/L). These isolates exhibited daptomycin, vancomycinTable 2
Antimicrobial activity and spectrum of telavancin and comparator agents against a wo
Genus MIC50, MIC90 (mg/L) and % susceptible
a f
Group Telavancin Vancom
Species (no. tested) MIC50 MIC90 %S MIC50
Staphylococcus spp. (1656)
Staphylococcus intermedius (11) 0.015 0.015 100.0 1 
Staphylococcus lugdunensis (258) 0.015 0.03 100.0 1 
Staphylococcus hominis (414) 0.015 0.06 100.0 1 
Staphylococcus simulans (48) 0.03 0.06 100.0 1 
Staphylococcus haemolyticus (425) 0.06 0.06 100.0 1 
Staphylococcus caprae (42) 0.06 0.06 100.0 1 
Staphylococcus cohnii (27) 0.06 0.06 100.0 1 
Staphylococcus capitis (214) 0.06 0.06 99.5 1 
Staphylococcus warneri (93) 0.06 0.06 100.0 1 
Staphylococcus saprophyticus (106) 0.06 0.12 98.1 1 
Staphylococcus pettenkoferi (18) 0.06 0.12 100.0 1 
Viridans group streptococci (1939)
Streptococcus anginosus group (627) 0.015 0.03 100.0 0.5 
Streptococcus anginosus (434) 0.015 0.03 100.0 0.5 
Streptococcus constellatus (157) 0.015 0.03 100.0 0.5 
Streptococcus intermedius (36) 0.015 0.06 100.0 0.5 
Streptococcus mitis group (1039)
Streptococcus gordonii (37) 0.03 0.06 100.0 0.5 
Streptococcus mitis/oralis (788) 0.015 0.03 99.9 0.5 
Streptococcus parasanguinis (101) 0.03 0.03 100.0 0.5 
Streptococcus sanguinis (113) 0.015 0.03 100.0 0.5 
Other viridans group streptococci
Streptococcus bovis/gallolyticus (126) 0.03 0.03 100.0 0.5 
Streptococcus mutans (14) 0.03 0.06 100.0 0.5 
Streptococcus salivarius (123) 0.015 0.03 99.2 0.5 
Streptococcus vestibularis (10) 0.015 0.015 100.0 0.5 
b-Haemolytic streptococci (157)
Streptococcus dysgalactiae (143) 0.015 0.03 100.0 0.25 
Streptococcus equisimilis (14) 0.015 0.06 100.0 0.25 
Other genera (69)
Corynebacterium spp. (34) 0.015 0.03 –c 0.25 
Listeria spp. (24) 0.015 0.03 – 1 
Micrococcus spp. (11) 0.015 0.015 – 0.25 
a Breakpoint criteria for telavancin according to the labelling supplement for the prod
breakpoint for telavancin against S. aureus (12 mg/L for susceptible) was used for staph
group (0.06 mg/L for susceptible), whilst the interpretive criterion for S. pyogenes a
streptococci [1]. Breakpoint criteria for comparator agents were those from the Clinica
b One S. sanguinis with a linezolid MIC of 32 mg/L [11].
c Breakpoint not available.and linezolid MIC values of 0.5–1, 0.5–2 and 0.5–2 mg/L,
respectively. In addition, the telavancin MIC50 and MIC90 results
tested against CoNS remained stable (0.03 mg/L and 0.06 mg/L,
respectively), regardless of the oxacillin susceptibility status (data
not shown).
Viridans group streptococci were very susceptible to telavancin
(99.9% susceptible at 0.06 mg/L), with MIC50 results of
0.015 mg/L or 0.03 mg/L (Tables 1 and 2). The comparator
agents, vancomycin and linezolid, had MIC50 values of 0.5 mg/L
and 0.5–1 mg/L, respectively. Daptomycin also showed MIC50
results of 0.25 mg/L and 0.5 mg/L, except for Streptococcus bovis/
gallolyticus (MIC50, 0.06 mg/L) and Streptococcus salivarius/
vestibularis (MIC50, 0.12 mg/L). One Streptococcus mitis and one
S. salivarius had non-susceptible results for telavancin (i.e. MIC,
0.12 mg/L). The S. mitis displayed MIC values of 2, 1 and 1 mg/L for
daptomycin, vancomycin and linezolid, respectively, whilst the S.
salivarius strain exhibited MIC results 0.12, 0.5 and 1 mg/L,
respectively (data not shown).
Telavancin (MIC50, 0.015 mg/L) and daptomycin (MIC50,
0.06 mg/L) showed greatest activities against Streptococcus
dysgalactiae and Streptococcus equisimilis, followed by vancomycin
(MIC50, 0.25 mg/L) and linezolid (MIC50, 1 mg/L) (Tables 1 and 2).
These four agents also inhibited all b-haemolytic streptococci at or
below their respective applied breakpoints for susceptibilityrldwide collection of clinical isolates.
or each agent
ycin Daptomycin Linezolid
MIC90 %S MIC50 MIC90 %S MIC50 MIC90 %S
1 100.0 0.12 0.25 100.0 0.5 1 100.0
1 100.0 0.25 0.25 100.0 0.5 0.5 100.0
2 100.0 0.25 0.5 100.0 0.5 1 99.8
1 100.0 0.25 0.5 100.0 1 1 97.9
2 100.0 0.25 0.5 100.0 0.5 1 99.5
1 100.0 0.5 0.5 100.0 0.5 1 100.0
1 100.0 0.5 0.5 100.0 1 2 96.3
1 100.0 0.5 1 99.5 0.5 1 99.1
2 100.0 0.5 1 100.0 0.5 1 100.0
2 100.0 0.5 0.5 100.0 1 1 100.0
2 100.0 1 2 83.3 0.25 0.5 100.0
1 100.0 0.25 0.5 99.8 1 1 100.0
1 100.0 0.25 0.5 99.8 1 1 100.0
1 100.0 0.25 0.5 100.0 0.5 1 100.0
1 100.0 0.25 0.5 100.0 0.5 1 100.0
0.5 100.0 0.5 1 100.0 0.5 1 100.0
0.5 100.0 0.5 1 99.2 0.5 1 100.0
0.5 100.0 0.5 1 98.0 1 1 100.0
0.5 100.0 0.25 0.5 100.0 0.5 1 99.1b
0.5 100.0 0.06 0.12 100.0 1 1 100.0
1 100.0 0.25 0.5 100.0 0.5 1 100.0
1 100.0 0.12 0.25 100.0 0.5 1 100.0
0.5 100.0 0.12 0.25 100.0 0.5 1 100.0
0.5 100.0 0.06 0.12 100.0 1 1 100.0
0.5 100.0 0.06 0.06 100.0 1 1 100.0
0.5 – 0.06 0.25 – 0.25 0.5 –
1 – 2 4 – 1 2 –
0.25 – 0.12 0.25 – 0.5 0.5 –
uct VIBATIV1, as available. The US Food and Drug Administration (FDA)-approved
ylococci. The breakpoint for viridans group streptococci was that from S. anginosus
nd S. agalactiae (0.12 mg/L for susceptible) was applied for other b-haemolytic
l and Laboratory Standards Institute (CLSI) [9].
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0.015/0.015 mg/L), Listeria spp. (MIC50/90, 0.015/0.03 mg/L)
and Corynebacterium spp. (MIC50/90, 0.015/0.03 mg/L) showed
telavancin MIC100 results of 0.015, 0.03 and 0.06 mg/L, respec-
tively (Table 1).
Because the reference broth microdilution method for tela-
vancin susceptibility testing was revised, this study was intended
to update the in vitro information and to re-establish the
benchmark for telavancin when tested against these uncommon
isolates. The species or group of species presented here also include
primary (i.e. S. anginosus group) and secondary (i.e. S. haemolyticus
and S. dysgalactiae) indicated organisms [1]. In addition, these in
vitro data conﬁrm the activity and spectrum of telavancin against
these less commonly encountered Gram-positive species, and
report telavancin potency greater than three comparator agents
(daptomycin, linezolid and vancomycin) with clinical indications
for treatment of uncomplicated and complicated SSTI.
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